ArticleWorld journal of gastroenterology2010
Hepatic osteodystrophy and liver cirrhosis.
Article in World journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Prevalent osteoporosis and fracture risk in patients with hepatic cirrhosis: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Prevalence of osteoporosis in chronic diseases: an umbrella review of 283 observational studies from 13 systematic reviews.BMC rheumatology · 2025Article
- Association between Chronic Hepatitis B/C and Incidence of Osteoporosis and Bone Fractures: Results from a Retrospective Cohort Study.Journal of clinical medicine · 2024Article
- Emerging role of liver-bone axis in osteoporosis.Journal of orthopaedic translation · 2024Review
- Exploring the impact of naltrexone on the THBS1/eNOS/NO pathway in osteoporotic bile duct-ligated rats.Scientific reports · 2024Article
- Osteoporosis and Fragility Fractures in Patients with Liver Cirrhosis: Usefulness of FRAXJournal of clinical medicine · 2023Article
- Vitamin D status & bone health in patients with liver cirrhosis.The Indian journal of medical research · 2023Article
- Article
- Article
- Prevalence and characteristics of bone disease in cirrhotic patients.Hepatology forum · 2020Article
- Article
- Bone Health and Impact of Tenofovir Treatment in Men with Hepatitis-B Related Chronic Liver Disease.Journal of clinical and experimental hepatology · 2018Article
- Reduced Serum IGF-1 Associated With Hepatic Osteodystrophy Is a Main Determinant of Low Cortical but Not Trabecular Bone Mass.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2018Article
- Article
- Risk factors for osteoporosis in patients with end-stage liver disease.Biomedical reports · 2016Article
- Cirrhosis-related musculoskeletal disease: radiological review.The British journal of radiology · 2016Review
- Osteoporosis in liver disease: pathogenesis and management.Therapeutic advances in endocrinology and metabolism · 2016Review
- Crucial Role of Vitamin D in the Musculoskeletal System.Nutrients · 2016Review
- Bone disease in cirrhosis.Clinical liver disease · 2015Review
- Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C.Digestive diseases and sciences · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the correlation between hepatic osteodystrophy and osteoporosis in patients with liver cirrhosis.
methodsBone mineral density of the patients (n = 55) and that of the control group (n = 30) were measured by dual-energy X-ray absorptiometry. All the women in the study were premenopausal. Deoxypyridinoline, pyridinoline and urinary Ca(2+) were measured as bone destruction markers, while alkaline phosphatase (ALP), osteocalcin and insulin-like growth factor-1 (IGF-1) were measured as bone formation markers. Furthermore, interleukin-1 (IL-1), IL-6, tumor necrosis factor alpha (TNF-alpha), vitamin D3, direct bilirubin, albumin, cortisol and parathyroid hormone (PTH) levels were measured. The independent Student t test and chi(2) test were employed in comparing both groups, and the Pearson correlation test was used to determine associations.
resultsComparing cirrhosis and control groups, lumbar total T-score (-1.6 + or - 1.2 g/cm(2) vs -0.25 + or - 1.3 g/cm(2), P < 0.001), lumbar total Z-score (-1.2 + or - 1.23 g/cm(2) vs -0.6 + or - 1.3 g/cm(2), P < 0.001), total femur T-score (-0.05 + or - 1 g/cm(2) vs -0.6 + or - 0.9 g/cm(2), P = 0.003) and total femur Z-score (-0.08 + or - 1.5 g/cm(2) vs 0.7 + or - 0.9 g/cm(2), P = 0.003) showed significantly lower values in the cirrhosis group. Blood ALP level (109.2 + or - 57 U/L vs 62.6 + or - 32.5 U/L, P < 0.001), IL-6 level (27.9 + or - 51.6 pg/mL vs 3.3 + or - 3.1 pg/mL, P = 0.01), TNF-alpha level (42.6 + or - 33.2 pg/mL vs 25.3 + or - 12.3 pg/mL, P = 0.007) and direct bilirubin level (0.9 + or - 0.7 mg/dL vs 0.3 + or - 0.2 mg/dL, P < 0.001) were significantly higher in the cirrhosis group. IGF-1 level (47.7 + or - 26.2 ng/mL vs 143.4 + or - 53.2 ng/mL, P < 0.001), osteocalcin level (1.05 + or - 2.5 ng/mL vs 7.0 + or - 13 ng/mL, P = 0.002) and 24 h urinary Ca(2+) (169.6 + or - 227.2 mg/dL vs 287 + or - 168.6 mg/dL, P = 0.003) were significantly lower in the cirrhosis group. Urinary deoxypyridinoline/creatinine (9.4 + or - 9.9 pmol/micromol vs 8.1 + or - 5.3 pmol/micromol, P = 0.51), urinary pyridinoline/creatinine (51.3 + or - 66.6 pmol/micromol vs 29 + or - 25.8 pmol/micromol, P = 0.08), blood IL-1 level (3.4 + or - 8.8 pg/mL vs 1.6 + or - 3.5 pg/mL, P = 0.29), vitamin D3 level (18.6 + or - 13.3 microg/L vs 18.4 + or - 8.9 microg/L, P = 0.95), cortisol level (11.1 + or - 4.8 microg/dL vs 12.6 + or - 4.3 microg/dL, P = 0.15) and PTH level (42.7 + or - 38 microg/dL vs 34.8 + or - 10.9 microg/dL, P = 0.27) were not significantly different.
conclusionHepatic osteodystrophy is an important complication encountered in patients with liver cirrhosis and all patients should be monitored for hepatic osteodystrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.